427 related articles for article (PubMed ID: 19224850)
1. First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy.
Inoue A; Kobayashi K; Usui K; Maemondo M; Okinaga S; Mikami I; Ando M; Yamazaki K; Saijo Y; Gemma A; Miyazawa H; Tanaka T; Ikebuchi K; Nukiwa T; Morita S; Hagiwara K;
J Clin Oncol; 2009 Mar; 27(9):1394-400. PubMed ID: 19224850
[TBL] [Abstract][Full Text] [Related]
2. Clinical outcomes after first-line EGFR inhibitor treatment for patients with NSCLC, EGFR mutation, and poor performance status.
Okuma Y; Hosomi Y; Nagamata M; Yamada Y; Sekihara K; Kato K; Hishima T; Okamura T
Anticancer Res; 2013 Nov; 33(11):5057-64. PubMed ID: 24222150
[TBL] [Abstract][Full Text] [Related]
3. First-line gefitinib in patients aged 75 or older with advanced non-small cell lung cancer harboring epidermal growth factor receptor mutations: NEJ 003 study.
Maemondo M; Minegishi Y; Inoue A; Kobayashi K; Harada M; Okinaga S; Morikawa N; Oizumi S; Tanaka T; Isobe H; Kudoh S; Hagiwara K; Nukiwa T; Gemma A
J Thorac Oncol; 2012 Sep; 7(9):1417-22. PubMed ID: 22895139
[TBL] [Abstract][Full Text] [Related]
4. Gefitinib for non-small-cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid PCR clamp.
Sutani A; Nagai Y; Udagawa K; Uchida Y; Koyama N; Murayama Y; Tanaka T; Miyazawa H; Nagata M; Kanazawa M; Hagiwara K; Kobayashi K
Br J Cancer; 2006 Dec; 95(11):1483-9. PubMed ID: 17106442
[TBL] [Abstract][Full Text] [Related]
5. Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations.
Inoue A; Suzuki T; Fukuhara T; Maemondo M; Kimura Y; Morikawa N; Watanabe H; Saijo Y; Nukiwa T
J Clin Oncol; 2006 Jul; 24(21):3340-6. PubMed ID: 16785471
[TBL] [Abstract][Full Text] [Related]
6. Prospective study of the accuracy of EGFR mutational analysis by high-resolution melting analysis in small samples obtained from patients with non-small cell lung cancer.
Fukui T; Ohe Y; Tsuta K; Furuta K; Sakamoto H; Takano T; Nokihara H; Yamamoto N; Sekine I; Kunitoh H; Asamura H; Tsuchida T; Kaneko M; Kusumoto M; Yamamoto S; Yoshida T; Tamura T
Clin Cancer Res; 2008 Aug; 14(15):4751-7. PubMed ID: 18676744
[TBL] [Abstract][Full Text] [Related]
7. Epidermal growth factor receptor genotype in plasma DNA and outcome of chemotherapy in the Chinese patients with advanced non-small cell lung cancer.
Zhuo ML; Wu MN; Zhao J; Song SW; Bai H; Wang SH; Yang L; An TT; Wang X; Duan JC; Wang YY; Guo QZ; Liu XY; Liu NH; Wang J
Chin Med J (Engl); 2011 Nov; 124(21):3510-4. PubMed ID: 22340169
[TBL] [Abstract][Full Text] [Related]
8. First-line gefitinib therapy for elderly patients with non-small cell lung cancer harboring EGFR mutation: Central Japan Lung Study Group 0901.
Takahashi K; Saito H; Hasegawa Y; Ando M; Yamamoto M; Kojima E; Sugino Y; Kimura T; Nomura F; Ogasawara T; Shindoh J; Yoshida N; Suzuki R
Cancer Chemother Pharmacol; 2014 Oct; 74(4):721-7. PubMed ID: 25087097
[TBL] [Abstract][Full Text] [Related]
9. Rapid detection of epidermal growth factor receptor mutations in lung cancer by the SMart-Amplification Process.
Hoshi K; Takakura H; Mitani Y; Tatsumi K; Momiyama N; Ichikawa Y; Togo S; Miyagi T; Kawai Y; Kogo Y; Kikuchi T; Kato C; Arakawa T; Uno S; Cizdziel PE; Lezhava A; Ogawa N; Hayashizaki Y; Shimada H
Clin Cancer Res; 2007 Sep; 13(17):4974-83. PubMed ID: 17785547
[TBL] [Abstract][Full Text] [Related]
10. A phase II study of pemetrexed monotherapy in chemo-naïve Eastern Cooperative Oncology Group performance status 2 patients with EGFR wild-type or unknown advanced non-squamous non-small cell lung cancer (HANSHIN Oncology Group 002).
Hata A; Katakami N; Fujita S; Nanjo S; Takeshita J; Tanaka K; Kaneda T; Nishiyama A; Nishimura T; Nakagawa A; Otsuka K; Morita S; Urata Y; Negoro S
Cancer Chemother Pharmacol; 2015 Jun; 75(6):1267-72. PubMed ID: 25925001
[TBL] [Abstract][Full Text] [Related]
11. Dominance of EGFR and insignificant KRAS mutations in prediction of tyrosine-kinase therapy for NSCLC patients stratified by tumor subtype and smoking status.
Pesek M; Benesova L; Belsanova B; Mukensnabl P; Bruha F; Minarik M
Anticancer Res; 2009 Jul; 29(7):2767-73. PubMed ID: 19596959
[TBL] [Abstract][Full Text] [Related]
12. Novel and existing mutations in the tyrosine kinase domain of the epidermal growth factor receptor are predictors of optimal resectability in malignant peritoneal mesothelioma.
Foster JM; Gatalica Z; Lilleberg S; Haynatzki G; Loggie BW
Ann Surg Oncol; 2009 Jan; 16(1):152-8. PubMed ID: 18998063
[TBL] [Abstract][Full Text] [Related]
13. Functional analysis of epidermal growth factor receptor (EGFR) mutations and potential implications for EGFR targeted therapy.
Kancha RK; von Bubnoff N; Peschel C; Duyster J
Clin Cancer Res; 2009 Jan; 15(2):460-7. PubMed ID: 19147750
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study.
Schiller JH; Larson T; Ou SH; Limentani S; Sandler A; Vokes E; Kim S; Liau K; Bycott P; Olszanski AJ; von Pawel J
J Clin Oncol; 2009 Aug; 27(23):3836-41. PubMed ID: 19597027
[TBL] [Abstract][Full Text] [Related]
15. Phase II randomized controlled trial of an epidermal growth factor vaccine in advanced non-small-cell lung cancer.
Neninger Vinageras E; de la Torre A; Osorio Rodríguez M; Catalá Ferrer M; Bravo I; Mendoza del Pino M; Abreu Abreu D; Acosta Brooks S; Rives R; del Castillo Carrillo C; González Dueñas M; Viada C; García Verdecia B; Crombet Ramos T; González Marinello G; Lage Dávila A
J Clin Oncol; 2008 Mar; 26(9):1452-8. PubMed ID: 18349395
[TBL] [Abstract][Full Text] [Related]
16. Epidermal growth factor receptor gene amplification in surgical resected Japanese lung cancer.
Sasaki H; Shimizu S; Okuda K; Kawano O; Yukiue H; Yano M; Fujii Y
Lung Cancer; 2009 Jun; 64(3):295-300. PubMed ID: 19058870
[TBL] [Abstract][Full Text] [Related]
17. Epidermal growth factor receptor mutation status and adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung.
Suehisa H; Toyooka S; Hotta K; Uchida A; Soh J; Fujiwara Y; Matsuo K; Ouchida M; Takata M; Kiura K; Date H
J Clin Oncol; 2007 Sep; 25(25):3952-7. PubMed ID: 17761979
[TBL] [Abstract][Full Text] [Related]
18. Effective inhibition of the epidermal growth factor/epidermal growth factor receptor binding by anti-epidermal growth factor antibodies is related to better survival in advanced non-small-cell lung cancer patients treated with the epidermal growth factor cancer vaccine.
García B; Neninger E; de la Torre A; Leonard I; Martínez R; Viada C; González G; Mazorra Z; Lage A; Crombet T
Clin Cancer Res; 2008 Feb; 14(3):840-6. PubMed ID: 18245547
[TBL] [Abstract][Full Text] [Related]
19. Epidermal growth factor receptor mutations in small cell lung cancer.
Tatematsu A; Shimizu J; Murakami Y; Horio Y; Nakamura S; Hida T; Mitsudomi T; Yatabe Y
Clin Cancer Res; 2008 Oct; 14(19):6092-6. PubMed ID: 18829487
[TBL] [Abstract][Full Text] [Related]
20. The peptide nucleic acid-locked nucleic acid polymerase chain reaction clamp-based test for epidermal growth factor receptor mutations in bronchoscopic cytological specimens of non-small cell lung cancer.
Yamada N; Oizumi S; Asahina H; Shinagawa N; Kikuchi E; Kikuchi J; Sakakibara-Konishi J; Tanaka T; Kobayashi K; Hagiwara K; Nishimura M
Oncology; 2012; 82(6):341-6. PubMed ID: 22677909
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
